The FDA has approved AstraZeneca’s and Merck’s Lynparza (olaparib) in combination with bevacizumab as a maintenance treatment for adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

The approval was based on the results of a phase 3 clinical trial, which showed that the combination reduced the risk of disease progression or death by 67 percent.

Lynparza was previously approved as a maintenance treatment of platinum-sensitive relapsed ovarian cancer.